Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
SOLENO THERAPEUTICS INC (SLNO)
|
Add to portfolio |
|
|
|
| Price: |
$0.47
| | Metrics |
| OS: |
9.99
|
M
| |
-229
|
% ROE
|
| Market cap: |
$4.68
|
M
| |
|
|
|
Net cash:
|
$19.4
|
M
| |
$1.94
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($26.0)
|
M
| |
|
|
|
EBIT
|
($28.0)
|
M
| |
|
|
| EPS |
($3.11)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
| Revenue growth | | | | | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 |
| Gross margin | | | | | | | | 41.9% |
| Selling, general and administrative | 24.4 | 31.5 | | | | | | |
| Sales and marketing | | | | | | 0.0 | | 1.7 |
| Research and development | | | 23.2 | 16.3 | 7.2 | 3.1 | 2.2 | 4.5 |
| General and administrative | | | 8.8 | 6.9 | 6.6 | 6.6 | 6.1 | 6.1 |
| EBIT | -23.8 | -30.8 | -31.9 | -23.2 | -11.7 | -9.7 | -8.3 | -12.3 |
| EBIT margin | | | | | | | | -2031.9% |
| Pre-tax income | -24.1 | -30.9 | -24.6 | -30.8 | -11.8 | -13.4 | -6.7 | -15.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 1.5 | -1.7 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | | 12.3% | 0.0% | 0.0% |
| Net income | -24.1 | -30.9 | -24.6 | -30.8 | -13.3 | -15.4 | -15.7 | -15.9 |
| Net margin | | | | | | | | -2618.8% |
| |
| Diluted EPS | ($2.87) | ($5.81) | ($0.39) | ($0.90) | ($0.56) | ($1.31) | ($5.07) | ($1.69) |
| Shares outstanding (diluted) | 8.4 | 5.3 | 62.6 | 34.1 | 21.0 | 9.0 | 3.1 | 9.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|